Previous studies have emphasized the association of anti-Ro/SSA antibodies with the development of extra-glandular manifestations such as cutaneous vasculitis, lung involvement, nephritis, and risk of lymphoma [8,9]. This evidence concerns the gene TRIM21 and cutaneous vasculitis.